CN103690502A - Ticagrelor sustained release preparation - Google Patents
Ticagrelor sustained release preparation Download PDFInfo
- Publication number
- CN103690502A CN103690502A CN201310754446.9A CN201310754446A CN103690502A CN 103690502 A CN103690502 A CN 103690502A CN 201310754446 A CN201310754446 A CN 201310754446A CN 103690502 A CN103690502 A CN 103690502A
- Authority
- CN
- China
- Prior art keywords
- adz6140
- slow
- immediate release
- release section
- released part
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to a sustained release preparation comprising Ticagrelor, a medicinal sustained-release material and other pharmaceutic adjuvants. The sustained release preparation comprises a quick release part and a sustained release part, is a dual-part tablet pressed by a dual-part tablet press, or a tablet taking a sustained release medicine as a tablet core and a quick release medicine as an external coating, or a sustained release capsule having quick release and sustained release parts. The sustained release preparation provided by the invention enables the medicines to take effects quickly, maintains the effective concentration of the medicines for a long period of time, and has a more ideal treatment effect.
Description
Technical field
The present invention relates to field of medicaments, relate in particular to a kind of ADZ6140 slow releasing preparation.
Background technology
ADZ6140 (Ticagrelor, once used code name: ADZ6140, ARC126532, also be translated as ticagrelor), belong to cyclopenta triazolopyrimidines, chemistry (1S by name, 2S, 3R, 5S)-3-[7-[(1R, 2S)-2-(3, 4-difluorophenyl) cyclopropylamino]-5-(thiopropyl)-3H-[1, 2, 3] triazole [4, 5-d] pyrimidin-3-yl]-5-(2-hydroxyl-oxethyl) Pentamethylene .-1, 2-glycol, English chemical name: (1S, 2S, 3R, 5S)-3-(7-((1R, 2S)-2-(3, 4-difluorophenyl) cyclopropylamino)-5-propylthio-3H-[1, 2, 3] triazo1o[4, 5-d] pyrimidin-3-y1)-5-(2-hydroxyethoxy) cyclopentane-1, 2-diol, molecular formula: C
23h
28f
2n
6o
45, molecular weight: 522.574, CAS registration number: a kind of new treatment acute coronary syndrome (the acute coronary syndrome that 274693-27-5 Shi You Britain AstraZeneca drugmaker (AstraZeneca) develops, ACS) medicine, this medicine is on July 20th, 2011 by U.S. FDA approval listing, and commodity are called Bril inta.
Though the ADZ6140 half-life only has 12 hours.After 12 hours, blood concentration is just down to half.For maintaining drug effect, will maintain blood concentration, thereby must take medicine every day 2 times.This is a kind of challenge to the not good patient of compliance.In practice, also find; approximately 20% patient who accepts Effect of Clopidogrel in Treating does not take medicine regularly as the doctor ordered; these patients are more impossible when using ADZ6140 to take in strict accordance with prescribed dose, and directly drug withdrawal probably increases the thrombotic risk of patients acuity, causes heart infarction or apoplexy.
Summary of the invention
Therefore, the object of the present invention is to provide a kind of ADZ6140 slow releasing preparation, another object of the present invention is to provide the preparation method of corresponding ADZ6140 slow releasing preparation.
ADZ6140 slow releasing preparation comprises: slow releasing tablet, slow releasing capsule, the dosage forms such as slow-releasing granules;
ADZ6140 slow releasing preparation comprises: immediate release section and slow-released part;
The weight range of ADZ6140 of the present invention in immediate release section, slow-released part is: ADZ6140 is 10mg-100mg in immediate release section; ADZ6140 is 50mg-180mg in slow-released part;
It is sustained-release matrix material that ADZ6140 immediate release section of the present invention contains at least one high molecular polymer, preferably hypromellose, hydroxypropyl cellulose, polyoxyethylene, hydroxyethyl-cellulose, polyvinyl alcohol, polyvinylpyrrolidone, acrylic copolymer etc.
ADZ6140 immediate release section of the present invention contains at least one pharmaceutic adjuvant and makes filler, preferably lactose, mannitol, microcrystalline Cellulose or calcium hydrogen phosphate.
Slow releasing preparation preferably a small amount of micropowder silica gel is made fluidizer,
ADZ6140 slow releasing preparation of the present invention contains a small amount of lubricant, preferably magnesium stearate, calcium stearate or stearic acid.
The preparation method of ADZ6140 slow releasing preparation of the present invention, comprises the steps: the preparation method of immediate release section, the preparation method of slow-released part.
Preparation technology can be: principal agent and adjuvant are crossed respectively to 100 mesh sieves.By the principal agent in immediate release section and the adjuvant mix homogeneously except magnesium stearate, with 70% ethanol soft material processed, 16 orders are granulated, and 60 ℃ dry, and 16 order granulate, add magnesium stearate as immediate release section granule; By the principal agent in slow-released part and the adjuvant mix homogeneously except magnesium stearate, with 70% ethanol soft material processed, 16 orders are granulated, and 50 ℃ dry, and 16 order granulate, add magnesium stearate as slow-released part granule; The double-layer sustained release tablets of preparing this ADZ6140 in bi-layer tablet press.
Preparation technology can be: principal agent and adjuvant are crossed respectively to 100 mesh sieves.By the principal agent in slow-released part and the adjuvant mix homogeneously except magnesium stearate, with 70% ethanol soft material processed, 16 orders are granulated, and 50 ℃ dry, and 16 order granulate, add magnesium stearate tabletting as slow-released part; Hypromellose in immediate release section is made into 5% aqueous solution, principal agent is added and make its suspendible even, utilize coating equipment in sugar production line that immediate release section is wrapped on slow-released part.
Preparation technology can be: principal agent and adjuvant are crossed respectively to 100 mesh sieves.Principal agent in immediate release section is mixed homogeneously with lactose, microcrystalline Cellulose, hypromellose is made into 3% aqueous solution as binding agent, with extruding rolling circle equipment, prepare fast release micropill; Principal agent in slow-released part is mixed homogeneously with hypromellose, microcrystalline Cellulose, with 70% ethanol, as binding agent, with extruding rolling circle equipment, prepare slow-release micro-pill; By two kinds of micropills difference film coatings, after mixing, incapsulate.
ADZ6140 slow releasing preparation of the present invention, ADZ6140 wherein can be prepared as ADZ6140 cyclodextrin or cyclodextrin derivant clathrate.
The preparation method of ADZ6140 cyclodextrin or cyclodextrin derivant clathrate in the present invention, also can be that cyclodextrin or cyclodextrin derivative are placed in to colloid mill or mortar, add appropriate suitable solvent to stir, make into pastel, according to the scope of weight ratio 1:3～10 of ADZ6140 and cyclodextrin or cyclodextrin derivative, ADZ6140 is added in above-mentioned pastel, grind 1～5 hour, obtain the viscous pastes of homogeneous, filter, lyophilization, obtains ADZ6140 cyclodextrin or cyclodextrin derivant clathrate.
ADZ6140 cyclodextrin or cyclodextrin derivant clathrate, have good water solubility, bland feature.After measured in the time of 25 ℃, the dissolubility of ADZ6140 hydroxypropyl-beta-cyclodextrin inclusion in water reaches 112mg/100ml, overcome ADZ6140 and can not prepare the shortcoming of water soluble preparation, owing to having improved water solublity, the solid preparation of preparing with it has the advantages that disintegrate is fast, stripping good, bioavailability is high, is more conducive to clinical practice.
ADZ6140 slow releasing tablet system formula provided by the invention and preparation method thereof, make an oral slow-releasing preparation product, make ADZ6140 after oral, in human body intestinal canal system, slowly discharge, maintain blood drug level, thereby make to take every day a deuterzooid slow releasing preparation product, can maintain the blood drug level of one day.
Embodiment:
Embodiment 1: the preparation of ADZ6140 slow releasing tablet
Preparation technology: principal agent and adjuvant are crossed respectively to 100 mesh sieves.By the principal agent in immediate release section and the adjuvant mix homogeneously except magnesium stearate, with 70% ethanol soft material processed, 16 orders are granulated, and 60 ℃ dry, and 16 order granulate, add magnesium stearate as immediate release section granule; By the principal agent in slow-released part and the adjuvant mix homogeneously except magnesium stearate, with 70% ethanol soft material processed, 16 orders are granulated, and 50 ℃ dry, and 16 order granulate, add magnesium stearate as slow-released part granule; The double-layer sustained release tablets of preparing this ADZ6140 in bi-layer tablet press.
Embodiment 2: the preparation of ADZ6140 slow releasing tablet
Preparation technology: principal agent and adjuvant are crossed respectively to 100 mesh sieves.By the principal agent in slow-released part and the adjuvant mix homogeneously except magnesium stearate, with 70% ethanol soft material processed, 16 orders are granulated, and 50 ℃ dry, and 16 order granulate, add magnesium stearate tabletting as slow-released part; Hypromellose in immediate release section is made into 5% aqueous solution, principal agent is added and make its suspendible even, utilize coating equipment in sugar production line that immediate release section is wrapped on slow-released part.
Embodiment 3: the preparation of ADZ6140 slow releasing capsule
Preparation technology: principal agent and adjuvant are crossed respectively to 100 mesh sieves.Principal agent in immediate release section is mixed homogeneously with lactose, microcrystalline Cellulose, hypromellose is made into 3% aqueous solution as binding agent, with extruding rolling circle equipment, prepare fast release micropill; Principal agent in slow-released part is mixed homogeneously with hypromellose, microcrystalline Cellulose, with 70% ethanol, as binding agent, with extruding rolling circle equipment, prepare slow-release micro-pill; By two kinds of micropills difference film coatings, after mixing, incapsulate.
Embodiment 4: the preparation of ADZ6140 slow releasing tablet
Preparation technology: principal agent and adjuvant are crossed respectively to 100 mesh sieves.
Take 90mg beta-schardinger dextrin-, pour in 400ml distilled water stirring and dissolving into; Separately take ADZ6140 30mg, pour in above-mentioned beta-schardinger dextrin-solution; Mixed liquor stirs 20 minutes with magnetic agitation method, mixing speed with liquid not outer spattering be advisable, observe solution to clear, filter, vacuum drying 4 hours, takes out and grinds and obtain ADZ6140 Benexate Hydrochloride.
By the ADZ6140 Benexate Hydrochloride in immediate release section and the adjuvant mix homogeneously except magnesium stearate, with 70% ethanol soft material processed, 16 orders are granulated, and 60 ℃ dry, and 16 order granulate, add magnesium stearate as immediate release section granule; By the principal agent in slow-released part and the adjuvant mix homogeneously except magnesium stearate, with 70% ethanol soft material processed, 16 orders are granulated, and 50 ℃ dry, and 16 order granulate, add magnesium stearate as slow-released part granule; The double-layer sustained release tablets of preparing this ADZ6140 in bi-layer tablet press.
Embodiment 5: the preparation of ADZ6140 slow releasing tablet
Preparation technology: principal agent and adjuvant are crossed respectively to 100 mesh sieves.
Take 70mg HP-β-CD, pour in 400m1 distilled water stirring and dissolving into; Separately take ADZ6140 20mg, pour in above-mentioned beta-schardinger dextrin-solution; Mixed liquor stirs 20 minutes with magnetic agitation method, mixing speed with liquid not outer spattering be advisable, observe solution to clear, filter, vacuum drying 4 hours, takes out and grinds and obtain ADZ6140 hydroxypropyl-beta-cyclodextrin inclusion.
By the principal agent in slow-released part and the adjuvant mix homogeneously except magnesium stearate, with 70% ethanol soft material processed, 16 orders are granulated, and 50 ℃ dry, and 16 order granulate, add magnesium stearate tabletting as slow-released part; Hypromellose in immediate release section is made into 5% aqueous solution, ADZ6140 hydroxypropyl-beta-cyclodextrin inclusion is added and make its suspendible even, utilize coating equipment in sugar production line that immediate release section is wrapped on slow-released part.
Embodiment 6: the preparation of ADZ6140 slow releasing capsule
Preparation technology: principal agent and adjuvant are crossed respectively to 100 mesh sieves.
Take 100mg HP-β-CD, pour in 400ml distilled water stirring and dissolving into; Separately take ADZ6140 30mg, pour in above-mentioned beta-schardinger dextrin-solution; Mixed liquor stirs 20 minutes with magnetic agitation method, mixing speed with liquid not outer spattering be advisable, observe solution to clear, filter, vacuum drying 4 hours, takes out and grinds and obtain ADZ6140 hydroxypropyl-beta-cyclodextrin inclusion.
ADZ6140 hydroxypropyl-beta-cyclodextrin inclusion in immediate release section is mixed homogeneously with lactose, microcrystalline Cellulose, hypromellose is made into 3% aqueous solution as binding agent, with extruding rolling circle equipment, prepare fast release micropill; Principal agent in slow-released part is mixed homogeneously with other adjuvants, with 70% ethanol, as binding agent, with extruding rolling circle equipment, prepare slow-release micro-pill; By two kinds of micropills difference film coatings, after mixing, incapsulate.
Embodiment 7:
The impact of product of the present invention on clotting time of mice.
1. experiment material animal: kunming mice, 20-22 gram.Reagent: normal saline, embodiment of the present invention 1-6 product, commercially available ADZ6140 sheet
2. experimental technique and result
Get healthy mice, be divided at random 15 groups, every group each 10, male and female half and half.Embodiment of the present invention 1-6 product, commercially available ADZ6140 sheet (respectively according to 2mg/kg.d, 4mg/kg.d) give gavage, normal group tail gavage normal saline.
After gavage, 30min gets blood from endocanthion with glass capillary, every 30s, fractures once, until there is the blood streak, records clotting time.
On the impact of mice blood clotting time (X ± SD)
Embodiment 8:
The impact of product of the present invention on experimental artery thrombosis.
1. experiment material
Animal: male Wistar rat (7 week age), body weight (250 ± 20) g, is divided into group at random, 10 every group.
Reagent: normal saline, embodiment of the present invention 1-6 product 1mg/kg.d, 2mg/kg.d, 4mg/kg.d, commercially available ADZ6140 sheet 1mg/kg.d, 2mg/kg.d, 4mg/kg.d, administration volume is 0.5ml/100g, continuous 7 days, after last administration 2h, with 20% urethane 1g/kg intraperitoneal anesthesia, dorsal position is fixed, separated carotid artery, and form with the experimental thrombus in vivo of BT87-3 type the formation time that instrument records arterial thrombus, the results are shown in Table.
ADZ6140 slow releasing tablet system formula provided by the invention and preparation method thereof, make an oral slow-releasing preparation product, make ADZ6140 after oral, in human body intestinal canal system, slowly discharge, maintain blood drug level, thereby make to take every day a deuterzooid slow releasing preparation product, can maintain the blood drug level of one day.
Release medium 0.2% tween 80 aqueous solution 900m1, constant temperature to 37 ℃, in the 75 slurry methods that turn, the product of embodiment 1-6 is measured, the specifications design of this product is 180mg, 1h discharges approximately 40%, later constant release to 20h reach 90%. this show, ADZ6140 slow releasing tablet of the present invention makes medicine continuous and effective in 12-24 hour, can slowly discharge at physiological condition, thereby patient can be taken once every day, improve the compliance that patient takes medicine, thereby further improved, prevent thrombotic curative effect.
Many aspects involved in the present invention have been done as above and have been set forth.Yet, it should be understood that before not departing from spirit of the present invention and put, those skilled in the art can be equal to and change and modify it, and described change and modification fall into the coverage of the application's claims equally.
Claims (10)
1. the present invention relates to a kind of ADZ6140 slow releasing preparation, it is characterized in that: comprising: immediate release section and slow-released part.
2. the present invention relates to a kind of ADZ6140 slow releasing preparation, it is characterized in that: comprising: immediate release section and slow-released part;
The weight range of ADZ6140 of the present invention in immediate release section, slow-released part is: ADZ6140 is 10mg-100mg in immediate release section; ADZ6140 is 50mg-180mg in slow-released part;
It is sustained-release matrix material that immediate release section contains at least one high molecular polymer, preferably hypromellose, hydroxypropyl cellulose, polyoxyethylene, hydroxyethyl-cellulose, polyvinyl alcohol, polyvinylpyrrolidone, acrylic copolymer etc.;
ADZ6140 immediate release section contains at least one pharmaceutic adjuvant and makes filler, preferred lactose, mannitol, microcrystalline Cellulose or calcium hydrogen phosphate;
Select a small amount of micropowder silica gel to make fluidizer,
Select a small amount of magnesium stearate, calcium stearate or stearic acid to make lubricant.
3. according to the ADZ6140 slow releasing preparation of claim 2, it is characterized in that: comprise the steps: the preparation method of immediate release section, the preparation method of slow-released part;
Preparation technology can be: principal agent and adjuvant are crossed respectively to 100 mesh sieves.By the principal agent in immediate release section and the adjuvant mix homogeneously except magnesium stearate, with 70% ethanol soft material processed, 16 orders are granulated, and 60 ℃ dry, and 16 order granulate, add magnesium stearate as immediate release section granule; By the principal agent in slow-released part and the adjuvant mix homogeneously except magnesium stearate, with 70% ethanol soft material processed, 16 orders are granulated, and 50 ℃ dry, and 16 order granulate, add magnesium stearate as slow-released part granule; The double-layer sustained release tablets of preparing this ADZ6140 in bi-layer tablet press.
Preparation technology can be: principal agent and adjuvant are crossed respectively to 100 mesh sieves.By the principal agent in slow-released part and the adjuvant mix homogeneously except magnesium stearate, with 70% ethanol soft material processed, 16 orders are granulated, and 50 ℃ dry, and 16 order granulate, add magnesium stearate tabletting as slow-released part; Hypromellose in immediate release section is made into 5% aqueous solution, principal agent is added and make its suspendible even, utilize coating equipment in sugar production line that immediate release section is wrapped on slow-released part.
Preparation technology can be: principal agent and adjuvant are crossed respectively to 100 mesh sieves.Principal agent in immediate release section is mixed homogeneously with lactose, microcrystalline Cellulose, hypromellose is made into 3% aqueous solution as binding agent, with extruding rolling circle equipment, prepare fast release micropill; Principal agent in slow-released part is mixed homogeneously with hypromellose, microcrystalline Cellulose, with 70% ethanol, as binding agent, with extruding rolling circle equipment, prepare slow-release micro-pill; By two kinds of micropills difference film coatings, after mixing, incapsulate.
4. according to the ADZ6140 slow releasing preparation of claim 3, it is characterized in that: ADZ6140 wherein can be prepared as ADZ6140 cyclodextrin or cyclodextrin derivant clathrate;
The preparation method of ADZ6140 cyclodextrin or cyclodextrin derivant clathrate in the present invention, also can be that cyclodextrin or cyclodextrin derivative are placed in to colloid mill or mortar, add appropriate suitable solvent to stir, make into pastel, according to the scope of weight ratio 1:3～10 of ADZ6140 and cyclodextrin or cyclodextrin derivative, ADZ6140 is added in above-mentioned pastel, grind 1～5 hour, obtain the viscous pastes of homogeneous, filter, lyophilization, obtains ADZ6140 cyclodextrin or cyclodextrin derivant clathrate.
5. according to the ADZ6140 slow releasing preparation of claim 3, it is characterized in that:
Immediate release section (every)
6. according to the ADZ6140 slow releasing preparation of claim 3, it is characterized in that:
7. according to the ADZ6140 slow releasing preparation of claim 3, it is characterized in that:
Immediate release section (every)
8. according to the ADZ6140 slow releasing preparation of claim 4, it is characterized in that:
Immediate release section (every)
Slow-released part (every)
9. according to the ADZ6140 slow releasing preparation of claim 4, it is characterized in that:
Immediate release section (every)
Slow-released part (every)
10. according to the ADZ6140 slow releasing preparation of claim 4, it is characterized in that:
Immediate release section (every)
Slow-released part (every)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310754446.9A CN103690502A (en) | 2013-12-31 | 2013-12-31 | Ticagrelor sustained release preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310754446.9A CN103690502A (en) | 2013-12-31 | 2013-12-31 | Ticagrelor sustained release preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103690502A true CN103690502A (en) | 2014-04-02 |
Family
ID=50352276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310754446.9A Pending CN103690502A (en) | 2013-12-31 | 2013-12-31 | Ticagrelor sustained release preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103690502A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106074357A (en) * | 2015-04-29 | 2016-11-09 | 江苏恒瑞医药股份有限公司 | A kind of ticagrelor or the preparation of its officinal salt |
| CN108210498A (en) * | 2016-12-15 | 2018-06-29 | 江苏恒瑞医药股份有限公司 | A kind of sustained release preparation of ticagrelor |
| CN110876732A (en) * | 2018-09-06 | 2020-03-13 | 江苏恒瑞医药股份有限公司 | Slow release composition of ticagrelor or pharmaceutically acceptable salt thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103520164A (en) * | 2013-10-30 | 2014-01-22 | 程刚 | Ticagrelor sustained-release preparation |
-
2013
- 2013-12-31 CN CN201310754446.9A patent/CN103690502A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103520164A (en) * | 2013-10-30 | 2014-01-22 | 程刚 | Ticagrelor sustained-release preparation |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106074357A (en) * | 2015-04-29 | 2016-11-09 | 江苏恒瑞医药股份有限公司 | A kind of ticagrelor or the preparation of its officinal salt |
| CN111544407A (en) * | 2015-04-29 | 2020-08-18 | 江苏恒瑞医药股份有限公司 | Ticagrelor preparation of pharmaceutically acceptable salt thereof |
| CN106074357B (en) * | 2015-04-29 | 2021-07-02 | 江苏恒瑞医药股份有限公司 | Ticagrelor preparation of pharmaceutically acceptable salt thereof |
| CN108210498A (en) * | 2016-12-15 | 2018-06-29 | 江苏恒瑞医药股份有限公司 | A kind of sustained release preparation of ticagrelor |
| CN110876732A (en) * | 2018-09-06 | 2020-03-13 | 江苏恒瑞医药股份有限公司 | Slow release composition of ticagrelor or pharmaceutically acceptable salt thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103520164B (en) | Ticagrelor sustained-release preparation | |
| TWI289063B (en) | Preparation with a good disintegrating property | |
| CN102657629B (en) | Ticagrelor sustained-release tablet system and preparation method thereof | |
| CN104434805B (en) | A kind of ticagrelor solid dispersions and preparation method thereof | |
| CN102548542A (en) | Tablet that disintegrates rapidly in the mouth and that contains two or more types of particles | |
| CN102091051B (en) | Allopurinol dual-release preparation and preparation method thereof | |
| CN107249590A (en) | Solid pharmaceutical preparation | |
| CN105456270A (en) | Dipeptidyl peptidase IV inhibitor pharmaceutical composition, use and preparation method thereof | |
| TW202038917A (en) | Extended release formulation containing tofacitinib or pharmaceutically acceptable salts thereof and preparation method for the same | |
| CN1903182B (en) | Miniaturization sarpogrelate hydrochloride oral drug-giving preparation | |
| CN103372014B (en) | A kind of energy Fast Stripping, stable Vardenafil hydrochloric acid oral solid formulation and preparation method thereof | |
| CN103690502A (en) | Ticagrelor sustained release preparation | |
| CN104873473A (en) | Potassium chloride sustained-release tablet and preparation method thereof | |
| JP2012051810A (en) | Orally disintegrable tablet and method for producing the same | |
| CN106511291A (en) | Acotiamide hydrochloride controlled release tablet and preparation method thereof | |
| WO2018159673A1 (en) | Erythritol granules and method for producing same, method for producing tablets using same, and tablets | |
| CN101422441B (en) | Nimesulide sustained-release tablet and preparation method thereof | |
| CN102657615A (en) | Vincamine sustained-release pellet preparation and preparation method thereof | |
| EP3345626A1 (en) | Super-rapid disintegrating tablet, and method for producing same | |
| CN112057429B (en) | Lei Xina Deg controlled release pharmaceutical composition | |
| JP5491727B2 (en) | Ribavirin oral tablets | |
| WO2019131411A1 (en) | Erythritol granules for orally disintegrating tablets, method for producing same, and orally disintegrating tablets prepared using same | |
| CN105555262A (en) | Intraorally disintegrable tablet comprising disintegrable granular composition | |
| CN104644601B (en) | Capecitabine tablet | |
| CN204072820U (en) | A kind of compound recipe three-layer tablet being used for the treatment of helicobacter pylori |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140402 |